Navigation Links
Auxilium Pharmaceuticals, Inc. Raises $50 Million In Additional Financing
Date:9/20/2013

patients with a palpable cord in the U.S. Ferring International Center S.A. markets Testim in certain countries of the EU and Paladin Labs Inc. markets Testim in Canada.  Swedish Orphan Biovitrium AB has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 71 Eurasian and African countries.  Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan and Actelion Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico.  Auxilium also markets TESTOPEL®, a long-acting implantable testosterone replacement therapy, Edex®, the leading branded non-oral drug for erectile dysfunction, Striant®, a buccal system for testosterone delivery, Osbon ErecAid®, the leading device for aiding erectile dysfunction, and also has a non-promoted respiratory franchise, including Theo-24® and Semprex®-D, along with three other non-promoted products, in the U.S.  Auxilium has three projects in clinical development.  XIAFLEX is in phase III of development for the treatment of Peyronie's disease.  CCH is in phase II of development for the treatment of Frozen Shoulder syndrome (adhesive capsulitis) and phase II of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy).  Auxilium also has rights to pursue additional indications for XIAFLEX. For additional information, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, which discuss matters that are not facts, and may include words to indicate their uncertain nature such as "believe," "expect," an
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. To Present At The Stifel Nicolaus Healthcare Conference
2. Auxilium Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference
4. Auxilium Pharmaceuticals, Inc, Announces Second Quarter 2013 Financial Results
5. Auxilium Pharmaceuticals to Announce Second Quarter 2013 Results and Conduct Conference Call on Thursday, August 1, 2013
6. New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix
7. Auxilium Pharmaceuticals, Inc. To Present At The Jefferies 2013 Healthcare Conference
8. Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference
9. Auxilium Pharmaceuticals, Inc. To Present At The UBS Global Health Care Conference
10. Auxilium Pharmaceuticals, Inc. To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
11. Auxilium Pharmaceuticals Completes Acquisition Of Actient Holdings LLC To Create A Leading Urology Franchise With A Diversified Product Portfolio And Strong Growth Profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015   KaloBios Pharmaceuticals, Inc . ... on developing innovative therapies to benefit patients with diseases ... announced today that the U.S. Food and Drug Administration ... application for KB003, an anti-GM-CSF monoclonal antibody (mAb), in ... IND is now active. The acceptance of ...
(Date:7/29/2015)... , July 29, 2015  The Perinatal ... to improve understanding of the advantages, limitations and ... screening and other diagnostic tests for pregnant women ... DGX ), the world,s leading provider of diagnostic ... support the initiative, through a grant. ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/-- LabStyle Innovations Corp. (DRIO), today ... a national broadcast news segment in Australia ... following regulatory and reimbursement approval in that country. ... 1.2 million Australians living with diabetes. As a case in ... great solution for a 13 year old boy with Type ...
Breaking Medicine Technology:KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 2KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 3KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 4KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 5Quest Diagnostics Collaborates with Perinatal Quality Foundation on National Initiative to Advance Clinically Appropriate Noninvasive Prenatal Screening 2Quest Diagnostics Collaborates with Perinatal Quality Foundation on National Initiative to Advance Clinically Appropriate Noninvasive Prenatal Screening 3Quest Diagnostics Collaborates with Perinatal Quality Foundation on National Initiative to Advance Clinically Appropriate Noninvasive Prenatal Screening 4LabStyle Innovations' Dario Diabetes Management Solution Featured on 9 News Australia 2LabStyle Innovations' Dario Diabetes Management Solution Featured on 9 News Australia 3
... N.C., Nov. 29, 2011 Campbell Alliance, an inVentiv ... specializing in the pharmaceutical and biotech industry, today ... 10 Most Licensable Oncology Projects to Watch.  Selected ... the upcoming Windhover Therapeutic Area Partnerships conference ( ...
... WELLESLEY HILLS, Mass., Nov. 29, 2011  Joseph F. Finn, ... of Epix Pharmaceuticals, Inc. ("Epix") announced today that AMG ... the S1P1 lead compounds will be offered December 8, ... generated by Epix Pharmaceuticals, Inc. and Amgen. ...
Cached Medicine Technology:Campbell Alliance Announces Windhover Top 10 Oncology Projects for 2011 2Campbell Alliance Announces Windhover Top 10 Oncology Projects for 2011 3AMG 277 Discriminates Against S1P3 Receptor by 50-fold. S1P1 Lead Compounds Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Assets Generated by Epix Pharmaceuticals, Inc. and Amgen. 2
(Date:7/29/2015)... ... ... The healthcare analytics market is categorized on the basis ... the rising pressure to curb healthcare costs, big data in healthcare, technological advancements, ... driving market growth. Check 149 data tables & 57 figures spread through 200 ...
(Date:7/29/2015)... ... , ... According to The Spirits Business on July 16th, a ... stimulating and perpetuating alcohol use disorders. Humans have the same gene, which is called ... of Sciences, and has given researchers inklings to explore Rsu1 in humans to abate ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to the Miami ... or alcohol addiction and mental health disorders. Acu-detox may begin taking off in the ... from drug and alcohol addiction. Although acupuncture is not a new practice, it is ...
(Date:7/29/2015)... San Fernando Valley, CA (PRWEB) , ... July 29, 2015 , ... ... offering a special promotional price on Ultherapy. For a limited time only, patients can ... Ultherapy is an option for patients who prefer a non-invasive treatment and have ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... Today marks ... Fund, which invests in women-led, growth companies and is led by a group of ... have responded positively, and voted with their dollars to be a part of the ...
Breaking Medicine News(10 mins):Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 2Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 3Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 4Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 5Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 2Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 3Health News:San Fernando Valley Dermatology Office, Castle Dermatology Institute, is Now Offering a Promotional Price on Ultherapy 2Health News:Sofia Fund Surpasses Investor Goals 2
... research shows , , FRIDAY, June 13 (HealthDay News) -- ... the morning may help ease some stresses you might ... rats inhaled the aroma of roasted coffee beans, a ... proteins with healthful antioxidant activity, the researchers reported. ...
... Md., June 13 EntreMed, Inc.,(Nasdaq: ... for the treatment of cancer and inflammatory ... and Chief Executive Officer,will present a Company ... Industry Organization 2008 Annual International Convention,being held ...
... blames traffic-related pollution for increasing the risk of allergy and ... more, the closer children live to roads, the higher their ... are likely to be exposed not only to a higher ... more freshly emitted aerosols which may be more toxic," wrote ...
... the most commonly ... June 13 Roche announced today that,its new test ... allowing it to be sold for clinical use in ... approach to help ensure,reliability of test results even when ...
... Arthritis is the Leading Cause of Work Disability ... data announced today,showed that treating patients with early, ... methotrexate (MTX) resulted in an,indirect cost savings of ... the time of the study) per patient per ...
... Lower Manhattan, the terrorist attacks of September 11, 2001, ... the Health Department,s World Trade Center Health Registry, show ... posttraumatic stress disorder (PTSD) two to three years after ... developed PTSD at three times the usual rate in ...
Cached Medicine News:Health News:Coffee Beans May Be Newest Stress-Buster 2Health News:Coffee Beans May Be Newest Stress-Buster 3Health News:EntreMed to Present at the BIO 2008 Annual International Convention 2Health News:Road pollution blamed for higher allergy risk in kids 2Health News:New Roche Chlamydia Test Approved for Use in European Union 2Health News:New Roche Chlamydia Test Approved for Use in European Union 3Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 2Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 3Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 4Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 5Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 6Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 7Health News:1 in 8 Lower Manhattan residents had signs of PTSD 2 to 3 years after 9/11 2
ELISA for the detection of Insulin....
... (17alpha-OH-P) is a steroid produced in the ... defined physiological role except as a precursor ... be converted to cortisol by the sequential ... the adrenal glands and ovaries, 17alpha-OH-P can ...
... PC1200 Platelet Incubators bring ... laboratory counter top. These compact ... to have the security of ... without taking up a large ...
The PC4200i is the largest capacity platelet incubator available. It features a built-in agitator with a capacity of 396 random bags (132 apheresis)....
Medicine Products: